ConvaTec Group Plc (CTEC.L) LSE
194.90
+0.9(+0.46%)
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
194.90
+0.9(+0.46%)
Currency In GBp
Address
3 Forbury Place
Reading, RG1 3JH
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 11 8952 8100
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Employees
10489
First IPO Date
October 26, 2016
| Name | Title | Pay | Year Born |
| Jonathan Mason | Chief Executive Officer & Director | 2.03M | 1964 |
| Fiona Victoria Ryder | Group Financial Controller, Chief Financial Officer & Director | 706,780 | 1975 |
| Emma Rose | EVP & Chief People Officer | 0 | N/A |
| Evelyn Douglas | EVP and Chief Strategy & Business Development Officer | 0 | N/A |
| Bruno Pinheiro | President & Chief Operating Officer of Ostomy Care | 0 | N/A |
| James Edward Spencer Kerton | EVP, General Counsel & Company Secretary | 0 | 1980 |
| Kjersti Grimsrud Biotechnology | President & Chief Operating Officer of Infusion Care | 0 | 1961 |
| Anne Belcher | President & Chief Operating Officer of Global Emerging Markets | 0 | N/A |
| Walter Morse | Interim Chief Quality & Operations Officer | 0 | N/A |
| Divakar Ramakrishnan | Chief Science, Innovation & Quality Officer | 0 | N/A |
| David Shepherd | Chief Commercial Officer | 0 | N/A |
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.